Britain’s biggest company AstraZeneca
has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.
The decision on the investment, which had been set to create 1,000 jobs, means none of the AstraZeneca’s planned new funding - originally announced in March 2024 - is currently proceeding.
In January, the company scrapped plans to invest 450 million pounds in its vaccine manufacturing plant in northern England, citing a cut in British government support.
U.S. drugmaker Merck & Co
